REPLIMUNE GROUP, INC. (REPL) Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 185.36M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $185.36M | (m) | (m) |
| 2026-03-31 | (m) | (m) | $209.02M | (m) | (m) |
| 2025-12-31 | (m) | (m) | $122.95M | (m) | (m) |
| 2025-09-30 | (m) | (m) | $102.30M | (m) | (m) |
| 2025-06-30 | (m) | (m) | $97.37M | (m) | (m) |
| 2025-03-31 | (m) | (m) | $111.12M | (m) | (m) |
| 2024-12-31 | (m) | (m) | $172.25M | (m) | (m) |
| 2024-09-30 | (m) | (m) | $113.49M | (m) | (m) |
| 2024-06-30 | (m) | (m) | $151.66M | (m) | (m) |
| 2024-03-31 | (m) | (m) | $74.46M | (m) | (m) |
| 2023-12-31 | (m) | (m) | $97.67M | (m) | (m) |
| 2023-09-30 | (m) | (m) | $76.00M | (m) | (m) |
| 2023-06-30 | (m) | (m) | $106.48M | (m) | (m) |
| 2023-03-31 | (m) | (m) | $146.59M | (m) | (m) |
| 2022-12-31 | (m) | (m) | $206.67M | (m) | (m) |
| 2022-09-30 | (m) | (m) | $88.93M | (m) | (m) |
| 2022-06-30 | (m) | (m) | $112.25M | (m) | (m) |
| 2022-03-31 | (m) | (m) | $105.95M | (m) | (m) |
| 2021-12-31 | (m) | (m) | $132.28M | (m) | (m) |
| 2021-09-30 | (m) | (m) | $159.97M | (m) | (m) |
| 2021-06-30 | (m) | (m) | $192.53M | (m) | (m) |
| 2021-03-31 | (m) | (m) | $182.52M | (m) | (m) |
| 2020-12-31 | (m) | (m) | $324.48M | (m) | (m) |
| 2020-09-30 | (m) | (m) | $43.33M | (m) | (m) |
| 2020-06-30 | (m) | (m) | $104.80M | (m) | (m) |
| 2020-03-31 | (m) | (m) | $59.50M | (m) | (m) |
| 2019-12-31 | (m) | (m) | $63.00M | (m) | (m) |
| 2019-09-30 | (m) | (m) | $53.30M | (m) | (m) |
| 2019-06-30 | (m) | (m) | $38.36M | (m) | (m) |
| 2019-03-31 | (m) | (m) | $25.70M | (m) | (m) |
| 2018-12-31 | (m) | (m) | $21.05M | (m) | (m) |
| 2018-09-30 | (m) | (m) | $23.28M | (m) | (m) |
| 2018-06-30 | (m) | (m) | $12.91M | (m) | (m) |
| 2018-03-31 | (m) | (m) | $17.58M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |